Top Back to top

Outcomes of HLA-mismatched HSCT in patients with PID following in vitro T-cell depletion with CD3+TCRαβ/CD19 depleted PBSC or in vivo T-cell depleted HSCT with post-transplant cyclophosphamide

Inborn Errors Working Party (IEWP)
Type d'étude:
Numéro de l'étude:
Type de traitement à base de cellules souches:
Allogeneic - Haploidentical
Other non-malignant disorders
Titre court:
TCR αβ or PTCY mismatched HSCT in PID
Objectif principal:
To compare overall and event free survival between the two groups. Events defined as graft failure, disease recurrence, severe chronic GVHD and severe autoimmunity or death
Principaux critères d'inclusion:
Diagnosis: Primary Immunodeficiency/Autoimmune/Autoinflammatory disorders
Type of HSCT: first HSCT with either CD3+TCR αβ/CD19 depletion in vitro or with post-transplant cyclophosphamide in vivo
Donors: mismatched donors, either haploidentical MMFD or ≤9/10 MMUD, BM and PBSC
Date of first date of HSCT: 1.1.2010-31.12.2018

If you wish to participate in this study and did not receive an invitation please contact:
Investigateur principal:
Mary Slatter & Michael Albert
Coordinateur EBMT de l'étude:
Sheree Hazelaar
E-mail du coordinateur de l'étude: